We are excited to announce the acquisition of a license for the groundbreaking Carbon-Platinum Nanozyme (CN-Pt NP) technology, pioneered by researchers at the University of Nevada, Reno. This cutting-edge innovation represents a significant leap forward in nanozyme performance and diagnostic assay capabilities.

Core Technology: CN-Pt Nanozymes

The licensed technology centers on a novel class of highly active peroxidase-mimicking nanozymes:

1. Synthesis: Utilizes a straightforward aqueous method to deposit ultrasmall platinum nanoparticles (Pt NPs, 1-2 nm) onto the surface of hydrophilic nitrogen-doped carbon nanoparticles (CN NPs).
2. Unprecedented Catalytic Activity: Achieves record-breaking catalytic constants:
   • 1.27 M·mL/s·g for substrate 3,3',5,5′-tetramethylbenzidine (TMB)
   • 1.97 M·mL/s·g for substrate hydrogen peroxide (H₂O₂)
3. Superior Performance: This K_cat is 1-2 orders of magnitude higher than previously reported carbon-noble metal nanozymes and many other inorganic peroxidase mimics, positioning CN-Pt NPs as the new benchmark for nanozyme efficiency.
4. Mechanism: The exceptional activity stems from a synergistic effect:
   • A protective hydrogen-bonded water layer facilitated by polar groups on the CN surface, preventing radical absorption and promoting reaction with TMB.
   • Ultra-small Pt size (~1-2 nm or atomic dispersion) maximizing active site density.
   • Electronic interactions between the carbon framework and Pt nanoparticles.

Key Advantages Over Existing Solutions:

• High Stability: Retains ~80% activity after 1 week at 4°C, significantly outperforming fragile natural enzymes like Horseradish Peroxidase (HRP).
• Robustness: Resistant to harsh chemical environments and temperature fluctuations (maintains >80% activity up to 45°C).
• Cost-Effectiveness: Uses minimal Pt (0.84 mg per synthesis) compared to traditional noble-metal nanozymes (20-40 mg).
• Simplified Logistics: Eliminates the need for cold-chain storage and transport required by HRP-based systems.
• Biocompatibility & Water Solubility: CN NPs provide excellent biocompatibility and aqueous dispersion.

Validated Application: Ultra-Sensitive Diagnostic Immunoassays

The licensed technology has been successfully demonstrated in a colorimetric magnetic bead-based sandwich immunoassay for detecting Burkholderia pseudomallei capsular polysaccharide (CPS), a Tier 1 select agent biomarker:

Exceptional Sensitivity:

• Limit of Detection (LOD) in PBS: 0.11 ng/mL
• LOD in Human Serum: 0.16 ng/mL
• Linear Range: ~0.5-50 ng/mL (PBS), ~1-50 ng/mL (Serum)

High Accuracy: Excellent recoveries (86-97%) and low coefficients of variation (0.8-4.03%) in spiked serum samples.

Performance Benchmark: Outperforms existing HRP-based ELISAs and other nanozyme-based assays for the same CPS biomarker.

We recognized the transformative potential of CN-Pt NPs to address critical limitations in current diagnostic tools, particularly the instability of natural enzymes and the modest activity of existing nanozymes. This technology offers:

1. Unmatched Signal Generation: The ultra-high K_cat enables faster and stronger signal amplification in bioassays, crucial for detecting low-abundance biomarkers.
2. Enhanced Assay Reliability & Shelf-Life: Superior stability reduces reagent degradation and assay variability.
3. Reduced Operational Costs: Lower noble metal usage and elimination of cold-chain requirements significantly decrease production and logistics expenses.
4. Platform Potential: The core CN-Pt NP technology is adaptable beyond CPS detection for a wide range of colorimetric, electrochemical, or photothermal diagnostic applications targeting other infectious diseases, cancers, or biomarkers.
5. Point-of-Care Viability: The robustness and stability make CN-Pt NPs ideal for developing reliable diagnostics deployable in resource-limited settings.

The CN-Pt nanozyme technology licensed by us represents a paradigm shift in diagnostic assay performance, offering unprecedented catalytic efficiency, stability, and cost-effectiveness. We are committed to leveraging this powerful platform to deliver transformative diagnostic solutions that improve patient outcomes worldwide.

Contact us for detailed information.